Original Article

You have full text access to this OnlineOpen article

Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma

  1. Helga B. Salvesen M.D., Ph.D.1,2,†,*,
  2. Ingunn Stefansson M.D.1,
  3. May Britt Kalvenes Ph.D.1,
  4. Soma Das Ph.D.3,
  5. Lars A. Akslen M.D., Ph.D.1

Article first published online: 15 APR 2002

DOI: 10.1002/cncr.10434

Issue

Cancer

Cancer

Volume 94, Issue 8, pages 2185–2191, 15 April 2002

Additional Information

How to Cite

Salvesen, H. B., Stefansson, I., Kalvenes, M. B., Das, S. and Akslen, L. A. (2002), Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer, 94: 2185–2191. doi: 10.1002/cncr.10434

Author Information

  1. 1

    Department of Pathology, The Gade Institute, Haukeland University Hospital, Bergen, Norway

  2. 2

    Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway

  3. 3

    Department of Human Genetics, The University of Chicago, Chicago, Illinois

  1. †

    Fax: 47 55 97 49 68

*Department of Gynecology and Obstetrics, Haukeland University Hospital, N-5021 Bergen, Norway

Publication History

  1. Issue published online: 15 APR 2002
  2. Article first published online: 15 APR 2002
  3. Manuscript Accepted: 9 NOV 2001
  4. Manuscript Revised: 16 OCT 2001
  5. Manuscript Received: 31 JUL 2001

Funded by

  • Norske Kvinners Sanitetsforening, the Norwegian Cancer Society. Grant Number: D96032/D94070
  • National Institutes of Health. Grant Number: CA81652-01
  • Blix Family Fund
  • Elena and Gustav B. Bull's Legacy

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (2353K)

REFERENCES

  • 1
    Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275: 1943–1947.
  • 2
    Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15: 356–362.
  • 3
    Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998; 280: 1614–1617.
  • 4
    Matsushima-Nishiu M, Unoki M, Ono K, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res. 2001; 61: 3741–3749.
  • 5
    Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997; 16: 64–67.
  • 6
    Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997; 57: 4997–5000.
  • 7
    Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995; 55: 1922–1926.
  • 8
    Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57: 3935–3940.
  • 9
    Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997; 17: 143–144.
  • 10
    Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997; 57: 4736–4738.
  • 11
    Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 2001; 61: 4311–4314.
  • 12
    Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res. 2000; 6: 153–159.
  • 13
    Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res. 1998; 4: 2779–2785.
  • 14
    Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol. 1999; 17: 1382–1390.
  • 15
    Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 1986; 155: 770–776.
  • 16
    Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999; 155: 1253–1260.
  • 17
    Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res. 2000; 6: 3607–3613.
  • 18
    McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999; 59: 4291–4296.
  • 19
    Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol. 1997; 104: 1302–1307.
  • 20
    Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 1993; 53: 5100–5103.
  • 21
    Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol. 2000; 31: 317.
  • 22
    Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998; 4: 3005–3010.
  • 23
    Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998; 95: 5246–5250.
  • 24
    Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001; 91: 22–26.
    Direct Link:
  • 25
    Mutter GL, Lin MC, Fitzgeld JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92: 924–930.
View Full Article (HTML) Get PDF (2353K)